Insights from 2023 ESMO Annual Meeting


 

ESMO 2023 Insights: "Randomized Phase 3 GASTFOX Study - 5-fluorouracil & Oxaliplatin +/- Docetaxel in the 1L Treatment of HER2- Locally Advanced Unresectable/Metastatic Gastric/GEJ Adenocarcinoma"

386 views
October 26, 2023
Comments 0
Login to view comments. Click here to Login